share_log

PreveCeutical Enters Into Loan Agreements

PreveCeutical Enters Into Loan Agreements

PreveCeutical进入贷款协议
newsfile ·  06/17 16:22

Vancouver, British Columbia--(Newsfile Corp. - June 17, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") announces that it has entered into a series of unsecured, non-convertible and interest-free loan agreements with, the Company's Chief Executive Officer, interim Chief Financial Officer and Chair, Stephen Van Deventer, and the Company's former President and director, Kimberly Van Deventer (collectively, the "Lenders"), in the aggregate amount of $297,731.00 (the "Loans").

不列颠哥伦比亚省温哥华(Newsfile Corp. - 2024年6月17日)- PreveCeutical Medical Inc.(CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("公司计划议程PreveCeutical本公司宣布已与首席执行官、临时财务总监和董事长史蒂芬·范德文特以及公司前总裁兼董事金伯利·范德文特(统称"公司利益相关方")签订了一系列未担保、不可转换、零利率的贷款协议,总金额为297,731.00美元("贷款")。放贷方"),总金额为297,731.00美元("贷款").

The proceeds of the Loans are intended to be used for working capital purposes.

贷款的所得将用于营运资本。

Stephen Van Deventer's participation is considered to be a "related party transaction" as defined under Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The Company has relied on the exemption from the minority shareholder approval requirement of MI 61-101 contained in section 5.7(1)(f) of MI 61-101 in respect of such insider participation.

史蒂芬·范德文特的参与被视为是《多边工具61-101 - 》("MI 61-101") 中所定义的"利益关联方交易"。董事会和全由独立董事组成的特别委员会(“特别委员会”)批准的该安排计划的背景和支持该安排的原因(“背景”);("mi 61-101公司已依据多边工具61-101中的5.7(1)(f)条所规定的豁免规定,就上述内幕人士的参与豁免少数股东批准要求。

About PreveCeutical

关于PreveCeutical

PreveCeutical is a health sciences company focused on developing innovative options for preventive and curative therapies utilizing organic and nature identical products. The Company aims to be a leader in the preventive health sciences sector.

PreveCeutical 是一家专注于开发利用有机和天然同源产品进行预防和治疗的创新选项的健康科学公司。该公司旨在成为预防卫生科学领域的领导者。

With the completion of three of its research programs, the Company is actively working on the development, clinical trials, and commercialization of its products; and has filed a number of provisional patent applications to protect the intellectual property from its research programs.

公司已完成三个研究项目,正在积极开展产品开发、临床试验和商业化,并已提交多项临时专利申请以保护研究项目的知识产权。

For more information about PreveCeutical, please visit our website or follow us on Twitter and Facebook.

欲了解更多PreveCeutical的资讯,请访问我们的网站或关注我们的Twitter和Facebook。

On behalf of the Board of Directors of PreveCeutical

谨代表PreveCeutical董事会

Stephen Van Deventer, Chairman, Chief Executive Officer and interim Chief Financial Officer

董事长、首席执行官兼临时财务总监 Stephen Van Deventer

For further information, please contact:

如需更多信息,请联系:

Stephen Van Deventer: +1 604 306 9669

Stephen Van Deventer:+1 604 306 9669

Or Investor Relations ir@preveceutical.com

或投资者关系业务ir@preveceutical.com

Forward-Looking Statements

前瞻性声明

Cautionary Note Regarding Forward-Looking Statements: This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified using forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or "occur". This information and these statements, referred to herein as "forward‐looking statements", are not historical facts, are made as of the date of this news release and include without limitation, statements regarding discussions of future plans, estimates and forecasts and statements as to management's expectations and intentions with respect to, among other things: the Company's anticipated use of proceeds of the Loans; and the Company's plans relating to the development, clinical trials and commercialization of its products.

关于前瞻性声明的警示: 本文包含可能构成适用加拿大证券法规中的前瞻性信息的某些声明和信息。前瞻性声明涉及未来事件或未来表现,并反映公司管理层对未来事件的预期或信念。一般而言,可以使用"打算"或"预计"这类意思的前瞻性词汇,或者使用此类词语和短语的变体或某些行动、事件或结果"可能"、"可能会"、"应该"、"将"或"发生"的声明,来识别前瞻性声明和信息。本文中的信息和这些声明(以下称为"前瞻性声明")不是历史事实,是截至本新闻发布日期的陈述,包括但不限于,未来计划、估算和预测的讨论以及管理层在公司发展、临床试验和产品商业化方面的期望和打算。

These forward‐looking statements involve numerous risks and uncertainties and actual results might differ materially from results suggested in any forward-looking statements. These risks and uncertainties include, among other things: the Company being unable to use the proceeds of the Loans as anticipated; the Company being unable to execute its business plans as intended; recent market volatility; and the state of the financial markets for the Company's securities.

此类前瞻性声明涉及许多风险和不确定性,实际结果可能与任何前瞻性声明所暗示的结果有所不同。这些风险和不确定性包括但不限于:公司可能无法按照预期使用贷款收益;公司可能无法按原意执行其业务计划;近期的市场波动和公司证券的金融市场状况。

In making the forward-looking statements in this news release, the Company has applied certain material assumptions, including without limitation, that: the Company will be able to use the proceeds of the Loans as anticipated; and the Company will be able to execute its business plans as intended.

在本新闻发布中发表前瞻性声明时,公司已经应用了某些实质性假设,包括但不限于:公司能够按照预期使用贷款收益;公司将能够按照原意执行其业务计划。

Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.

虽然本公司管理层已努力确定可能导致实际结果与前瞻性声明或前瞻性信息不同的重要因素,但可能存在其他因素使得结果不如预期、估计或意图。因此,读者不应过分依赖前瞻性声明和前瞻性信息。读者要注意,对这些信息的依赖可能不适合其他目的。公司不承担更新任何以此处引用的前瞻性声明、前瞻性信息或财务展望的义务,除非依照适用的证券法。感谢支持。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发